The Significance Of The Improvement Of Cardiac Function And Quality Of Life In Hemodialysis Patients With End-stage Renal Disease By Sacubitril Valsartan

Objective: To investigate the significance of improving cardiac function in end-stage renal disease patients undergoing hemodialysis with Sacubitril/Valsartan.Method: A retrospective analysis was conducted on the clinical data of 40 patients with end-stage renal disease complicated with chronic heart failure on maintenance hemodialysis at the Wuhan Third Hospital Hemodialysis Center from January 2021 to December 2022.Among them,20 patients in the treatment group were treated with the replacement of the original angiotensin converting enzyme inhibitor(ACEI)/angiotensin II receptor blocker(ARB)with the replacement of Sacubitril/Valsartan(SV),while 20 patients in the control group continued treatment with the original ACEI/ARB.Collect blood sampling tests and cardiac ultrasound results from patients before and 6 months after treatment.Use the Kidney Disease Quality of Life Scale(KDQOL)score to evaluate the quality of life before and after treatment in both groups.Result: Compared before treatment and 6 months after treatment,the treatment group showed a decrease in blood BNP(P<0.05),a decrease in left atrium,left ventricular diameter,and right ventricular outflow tract(P<0.05)as indicated by echocardiography,and an increase in EF(P<0.05),with a significantly higher amplitude than the control group;Control group: Blood BNP decreased,but the difference was not statistically significant(P>0.05).Cardiac ultrasound showed an increase in EF(P<0.05);The KDQOL scores of both groups decreased(P<0.05),and the decrease in SV treatment group was higher than that of the control group;Conclusion: Compared with ACEI/ARB,Sacubitril/Valsartan can significantly improve the cardiac structure,function,and quality of life of patients with end-stage renal disease undergoing maintenance hemodialysis combined with chronic heart failure.